Doctor Daniel Greenwald reflects on decisions to treat a woman with newly diagnosed follicular lymphoma with obinutuzumab-based immunochemotherapy and maintenance therapy.
EP. 1: Case Impressions: A Woman With Newly Diagnosed Follicular Lymphoma
Similarities between the management of a hypothetical case of newly diagnosed follicular lymphoma compared with what is done in real-world practice.
EP. 2: Criteria Used in the Initial Diagnosis of Follicular Lymphoma
Recommendations for assessing and risk stratifying patients with newly diagnosed follicular lymphoma, with special considerations regarding the current role of molecular testing.
EP. 3: Newly Diagnosed Follicular Lymphoma: Frontline Treatment Decisions
Goals of therapy and variables that affect how patients with newly diagnosed follicular lymphoma are managed with chemoimmunotherapy in the frontline setting, including during COVID-19.
EP. 4: Newly Diagnosed Follicular Lymphoma: First-Line Anti-CD20 Therapy
The rationale for treating newly diagnosed follicular lymphoma with the anti-CD20 monoclonal antibody, obinutuzumab, in the first-line setting.
EP. 5: Maintenance Therapy for Newly Diagnosed Follicular Lymphoma
Factors that affect the use of maintenance therapy, including anti-CD20 maintenance therapy, for newly diagnosed follicular lymphoma, and recommendations for assessing response to therapy.
EP. 6: Managing Early Progression in Follicular Lymphoma
Treatment options and variables that need to be considered when managing patients with follicular lymphoma who relapse early after first-line chemoimmunotherapy.
EP. 7: Tailored Treatment Approaches for Newly Diagnosed Follicular Lymphoma
Treatment advice for community oncologists and hematologists who treat follicular lymphoma based on therapeutic advances occurring rapidly in the field.
2 Commerce Drive Cranbury, NJ 08512